NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Faeth Therapeutics, Inc. (FTH) Stock Analysis

Faeth Therapeutics, Inc. (FTH) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

FTH

$40.05

+$1.05 (+2.69%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FTH with… →

FTH Key Statistics

As of Sep 4, 2026
Trading
Open
$38.35
Previous Close
$39.00
Day's Range
38.35–41.16
52-Week Range
7.45–41.16
Volume
275.25K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.28
Valuation
Market Cap
$1.03B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−60.86
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$21.09M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
25.84M
1-Year Return
+354.39%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
242.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

FTH Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+275.35%
2025+8.88%
2024−29.19%
2023−53.56%
2022−74.31%
2021 (partial year)−69.31%

As of September 4, 2026.

FTH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$21.09M—
2024$0.00−$30.16M—
2023$0.00−$34.10M—
2022$0.00−$48.59M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$22.29M−$21.09M—
2024$0.00—−$31.66M−$30.16M—
2023$0.00—−$37.06M−$34.10M—
2022$0.00—−$50.19M−$48.59M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

FTH Valuation vs Biotechnology Median

Median of 654 stocks
MetricFTHBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 654 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Faeth Therapeutics, Inc. (FTH) is capitalised at $1.03B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 29 employees.

FTH last closed at $40.05 on September 4, 2026. That is +$1.05 (+2.69%) against the previous close. Over the past 52 weeks the price has ranged from $7.45 to $41.16. The latest close sits 437.58% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $21.09M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −60.86.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Beta against the wider market is reported at −0.28. Annualized volatility over the trailing 5 years is 134%. Over the trailing twelve months the price has returned +354.39%. Measured over 5 years, that is −30.04% a year compounded.

Growth & Income

The record shows no dividend for FTH.

The strongest complete calendar year on file is 2025 at +8.88%; the weakest is 2022 at −74.31%. Of the 4 complete calendar years on file, 1 finished higher. So far in 2026 the price is +275.35%.

Peer Comparison

Faeth Therapeutics, Inc. (FTH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Faeth Therapeutics, Inc. FTH $1.03B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 31.8
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 39.4

The Biotechnology industry average P/E ratio is 12.9x. Faeth Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Sensei Biotherapeutics, Inc. and changed its name to Faeth Therapeutics, Inc. in June 2026. The company was incorporated in 1999 and is headquartered in Rockville, Maryland.

Visit website →